---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-100801"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:18:36.739279+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience raises $50M in PIPE; accelerates ALTO-207 in TRD after FDA meeting

## Summary
- Gross proceeds of ~$50M from PIPE led by Perceptive Advisors; priced at $5.914/share plus pre-funded warrants at $5.9139.
- Proceeds to accelerate ALTO-207 development in treatment-resistant depression; Phase 2b potentially pivotal by mid-2026, Phase 3 by early 2027.
- Successful FDA meeting for ALTO-207 guides accelerated path; blinded PK data from ALTO-100 and ALTO-101 showed 96% and 100% compliance.
- Terminated $75M Sales Agreement with Leerink Partners; no shares sold under it.
- Cash runway extended into 2028 including additional ALTO-207 activities.

## SEC filing metadata
- accession: 0001104659-25-100801
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/0001104659-25-100801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-100801
- JSON: https://secwatch.observer/filing/0001104659-25-100801.json
- Plain text: https://secwatch.observer/filing/0001104659-25-100801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.